Swiss psychoanalyst Hermann Rorschach formalized this idea through the inkblot test he created—he noticed that people with schizophrenia tended to perceive the images differently than did other ...

The phase 2 trial represented a key test of that idea ... after five weeks in a phase 3 trial that enrolled 256 people with schizophrenia experiencing acute psychosis. Neurocrine Biosciences ...

Peptide antigen-associated IgG levels were significantly lower in drug-naïve patients with first episode psychosis compared to control individuals.

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials.

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...